Science 9 September 1994: Vol. 265. no. 5178, pp. 1582 - 1584 DOI: 10.1126/science.7521539

Prev | Table of Contents | Next

Articles

Activation of Host Wound Responses in Breast Cancer Microenvironment.

M. A. Troester, M. H. Lee, M. Carter, C. Fan, D. W. Cowan, E. R. Perez, J. R. Pirone, C. M. Perou, D. J. Jerry, and S. S. Schneider (2009)
Clin. Cancer Res. 15, 7020-7028
 |  Abstract »  |  Full Text »  |  PDF »

Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins.

T.-Y. Lee, S. Muschal, E. A. Pravda, J. Folkman, A. Abdollahi, and K. Javaherian (2009)
Blood 114, 1987-1998
 |  Abstract »  |  Full Text »  |  PDF »

Thrombospondin-1 Is a Transcriptional Repression Target of PRMT6.

J. Michaud-Levesque and S. Richard (2009)
J. Biol. Chem. 284, 21338-21346
 |  Abstract »  |  Full Text »  |  PDF »

Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.

S.-Y. Kang, O. J. Halvorsen, K. Gravdal, N. Bhattacharya, J. M. Lee, N. W. Liu, B. T. Johnston, A. B. Johnston, S. A. Haukaas, K. Aamodt, et al. (2009)
PNAS 106, 12115-12120
 |  Abstract »  |  Full Text »  |  PDF »

Elongation Factor ELL (Eleven-Nineteen Lysine-rich Leukemia) Acts as a Transcription Factor for Direct Thrombospondin-1 Regulation.

J. Zhou, X. Feng, B. Ban, J. Liu, Z. Wang, and W. Xiao (2009)
J. Biol. Chem. 284, 19142-19152
 |  Abstract »  |  Full Text »  |  PDF »

{beta}1 Integrin Cytoplasmic Variants Differentially Regulate Expression of the Antiangiogenic Extracellular Matrix Protein Thrombospondin 1.

H. L. Goel, L. Moro, J. E. Murphy-Ullrich, C.-C. Hsieh, C.-L. Wu, Z. Jiang, and L. R. Languino (2009)
Cancer Res. 69, 5374-5382
 |  Abstract »  |  Full Text »  |  PDF »

Vasohibin-1 Expression in Endothelium of Tumor Blood Vessels Regulates Angiogenesis.

T. Hosaka, H. Kimura, T. Heishi, Y. Suzuki, H. Miyashita, H. Ohta, H. Sonoda, T. Moriya, S. Suzuki, T. Kondo, et al. (2009)
Am. J. Pathol. 175, 430-439
 |  Abstract »  |  Full Text »  |  PDF »

Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma.

L. H. Baker, E. K. Rowinsky, D. Mendelson, R. A. Humerickhouse, R. A. Knight, J. Qian, R. A. Carr, G. B. Gordon, and G. D. Demetri (2008)
J. Clin. Oncol. 26, 5583-5588
 |  Abstract »  |  Full Text »  |  PDF »

AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer.

B. Nie, Z. Shen, J.-B. Wen, O. G.-W. Wong, W. D. Hsueh, L.-F. Huo, H.-F. Kung, B. Jiang, and M. C.M. Lin (2008)
Mol. Cancer Ther. 7, 2855-2865
 |  Abstract »  |  Full Text »  |  PDF »

Spironolactone Suppresses Peritubular Capillary Loss and Prevents Deoxycorticosterone Acetate/Salt-Induced Tubulointerstitial Fibrosis.

Y. Iwazu, S. Muto, G. Fujisawa, E. Nakazawa, K. Okada, S. Ishibashi, and E. Kusano (2008)
Hypertension 51, 749-754
 |  Abstract »  |  Full Text »  |  PDF »

Novel Quinazoline-Based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity.

J. B. Garrison, Y.-J. Shaw, C.-S. Chen, and N. Kyprianou (2007)
Cancer Res. 67, 11344-11352
 |  Abstract »  |  Full Text »  |  PDF »

Thrombospondin-1 and Thrombospondin-2 mRNA and TSP-1 and TSP-2 Protein Expression in Uterine Fibroids and Correlation to the Genes COL1A1 and COL3A1 and to the Collagen Cross-link Hydroxyproline.

M. A. Behera, L. Feng, B. Yonish, W. Catherino, S.-H. Jung, and P. C. Leppert (2007)
Reproductive Sciences 14, 63-76
 |  Abstract »  |  PDF »

Nonclassic Endogenous Novel Regulators of Angiogenesis.

D. Ribatti, M. T. Conconi, and G. G. Nussdorfer (2007)
Pharmacol. Rev. 59, 185-205
 |  Abstract »  |  Full Text »  |  PDF »

Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis.

B. Doyle and N. Caplice (2007)
J. Am. Coll. Cardiol. 49, 2073-2080
 |  Abstract »  |  Full Text »  |  PDF »

Activating Transcription Factor-1-mediated Hepatocyte Growth Factor-induced Down-regulation of Thrombospondin-1 Expression Leads to Thyroid Cancer Cell Invasion.

C. Ghoneim, M. Soula-Rothhut, C. Blanchevoye, L. Martiny, F. Antonicelli, and B. Rothhut (2007)
J. Biol. Chem. 282, 15490-15497
 |  Abstract »  |  Full Text »  |  PDF »

Calcitriol Is a Potent Inhibitor of Retinal Neovascularization.

D. M. Albert, E. A. Scheef, S. Wang, F. Mehraein, S. R. Darjatmoko, C. M. Sorenson, and N. Sheibani (2007)
Invest. Ophthalmol. Vis. Sci. 48, 2327-2334
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis.

R. R. Langley and I. J. Fidler (2007)
Endocr. Rev. 28, 297-321
 |  Abstract »  |  Full Text »  |  PDF »

p53 therapy in a patient with Li-Fraumeni syndrome.

N. Senzer, J. Nemunaitis, M. Nemunaitis, J. Lamont, M. Gore, H. Gabra, R. Eeles, N. Sodha, F. J. Lynch, L. A. Zumstein, et al. (2007)
Mol. Cancer Ther. 6, 1478-1482
 |  Abstract »  |  Full Text »  |  PDF »

Possible Role of Semaphorin 3F, a Candidate Tumor Suppressor Gene at 3p21.3, in p53-Regulated Tumor Angiogenesis Suppression.

M. Futamura, H. Kamino, Y. Miyamoto, N. Kitamura, Y. Nakamura, S. Ohnishi, Y. Masuda, and H. Arakawa (2007)
Cancer Res. 67, 1451-1460
 |  Abstract »  |  Full Text »  |  PDF »

Preclinical Evaluation of Antiangiogenic Thrombospondin-1 Peptide Mimetics, ABT-526 and ABT-510, in Companion Dogs with Naturally Occurring Cancers.

A. Rusk, E. McKeegan, F. Haviv, S. Majest, J. Henkin, and C. Khanna (2006)
Clin. Cancer Res. 12, 7444-7455
 |  Abstract »  |  Full Text »  |  PDF »

Cooperative Activity of Cytotoxic Chemotherapy with Antiangiogenic Thrombospondin-I Peptides, ABT-526 in Pet Dogs with Relapsed Lymphoma.

A. Rusk, E. Cozzi, M. Stebbins, D. Vail, J. Graham, V. Valli, J. Henkin, R. Sharpee, and C. Khanna (2006)
Clin. Cancer Res. 12, 7456-7464
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification.

A. P. Mitra, R. H. Datar, and R. J. Cote (2006)
J. Clin. Oncol. 24, 5552-5564
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin.

J. Folkman (2006)
Sci. STKE 2006, pe35
 |  Abstract »  |  Full Text »  |  PDF »

Overexpression of Hypoxia-Inducible Factor 1{alpha} and p53 Is a Marker for an Unfavorable Prognosis in Gastric Cancer.

Y. Sumiyoshi, Y. Kakeji, A. Egashira, K. Mizokami, H. Orita, and Y. Maehara (2006)
Clin. Cancer Res. 12, 5112-5117
 |  Abstract »  |  Full Text »  |  PDF »

p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase..

J. G. Teodoro, A. E. Parker, X. Zhu, and M. R. Green (2006)
Science 313, 968-971
 |  Abstract »  |  Full Text »  |  PDF »

Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.

G. Qin, R. Kishore, C. M. Dolan, M. Silver, A. Wecker, C. N. Luedemann, T. Thorne, A. Hanley, C. Curry, L. Heyd, et al. (2006)
PNAS 103, 11015-11020
 |  Abstract »  |  Full Text »  |  PDF »

Cyclin D1 Regulates Cellular Migration through the Inhibition of Thrombospondin 1 and ROCK Signaling..

Z. Li, C. Wang, X. Jiao, Y. Lu, M. Fu, A. A. Quong, C. Dye, J. Yang, M. Dai, X. Ju, et al. (2006)
Mol. Cell. Biol. 26, 4240-4256
 |  Abstract »  |  Full Text »  |  PDF »

Targeting Angiogenesis With Integrative Cancer Therapies.

D. R. Yance Jr and S. M. Sagar (2006)
Integr Cancer Ther 5, 9-29
 |  Abstract »  |  PDF »

Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us why..

M. Narazaki and G. Tosato (2006)
J Natl Cancer Inst 98, 294-295
 |  Full Text »  |  PDF »

The Biological Impact of the Human Master Regulator p53 Can Be Altered by Mutations That Change the Spectrum and Expression of Its Target Genes..

D. Menendez, A. Inga, and M. A. Resnick (2006)
Mol. Cell. Biol. 26, 2297-2308
 |  Abstract »  |  Full Text »  |  PDF »

Pituitary Tumor-Transforming Gene Regulates Multiple Downstream Angiogenic Genes in Thyroid Cancer.

D. S. Kim, J. A. Franklyn, A. L. Stratford, K. Boelaert, J. C. Watkinson, M. C. Eggo, and C. J. McCabe (2006)
J. Clin. Endocrinol. Metab. 91, 1119-1128
 |  Abstract »  |  Full Text »  |  PDF »

Type I Collagen Limits VEGFR-2 Signaling by a SHP2 Protein-Tyrosine Phosphatase-Dependent Mechanism 1.

S. Mitola, B. Brenchio, M. Piccinini, L. Tertoolen, L. Zammataro, G. Breier, M. T. Rinaudo, J. den Hertog, M. Arese, and F. Bussolino (2006)
Circ. Res. 98, 45-54
 |  Abstract »  |  Full Text »  |  PDF »

Tumour proliferation, angiogenesis, and ploidy status in human colon cancer.

E Cristi, G Perrone, G Toscano, A Verzi, S Nori, D Santini, G Tonini, A Vetrani, A Fabiano, and C Rabitti (2005)
J. Clin. Pathol. 58, 1170-1174
 |  Abstract »  |  Full Text »  |  PDF »

Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1.

L. A. Ridnour, J. S. Isenberg, M. G. Espey, D. D. Thomas, D. D. Roberts, and D. A. Wink (2005)
PNAS 102, 13147-13152
 |  Abstract »  |  Full Text »  |  PDF »

The N-terminal Module of Thrombospondin-1 Interacts with the Link Domain of TSG-6 and Enhances Its Covalent Association with the Heavy Chains of Inter-{alpha}-trypsin Inhibitor.

S. A. Kuznetsova, A. J. Day, D. J. Mahoney, M. S. Rugg, D. F. Mosher, and D. D. Roberts (2005)
J. Biol. Chem. 280, 30899-30908
 |  Abstract »  |  Full Text »  |  PDF »

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer.

R. Hoekstra, F. Y.F.L. de Vos, F. A.L.M. Eskens, J. A. Gietema, A. van der Gaast, H. J.M. Groen, R. A. Knight, R. A. Carr, R. A. Humerickhouse, J. Verweij, et al. (2005)
J. Clin. Oncol. 23, 5188-5197
 |  Abstract »  |  Full Text »  |  PDF »

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab.

W. L. Ince, A. M. Jubb, S. N. Holden, E. B. Holmgren, P. Tobin, M. Sridhar, H. I. Hurwitz, F. Kabbinavar, W. F. Novotny, K. J. Hillan, et al. (2005)
J Natl Cancer Inst 97, 981-989
 |  Abstract »  |  Full Text »  |  PDF »

A Genomic Map of p53 Binding Sites Identifies Novel p53 Targets Involved in an Apoptotic Network.

C. Miled, M. Pontoglio, S. Garbay, M. Yaniv, and J. B. Weitzman (2005)
Cancer Res. 65, 5096-5104
 |  Abstract »  |  Full Text »  |  PDF »

Kringle 5 of Human Plasminogen Induces Apoptosis of Endothelial and Tumor Cells through Surface-Expressed Glucose-Regulated Protein 78.

D. J. Davidson, C. Haskell, S. Majest, A. Kherzai, D. A. Egan, K. A. Walter, A. Schneider, E. F. Gubbins, L. Solomon, Z. Chen, et al. (2005)
Cancer Res. 65, 4663-4672
 |  Abstract »  |  Full Text »  |  PDF »

P53 Mutation Analysis of Colorectal Liver Metastases: Relation to Actual Survival, Angiogenic Status, and p53 Overexpression.

K. P. de Jong, A. S.H. Gouw, P. M.J.G. Peeters, M. Bulthuis, L. Menkema, R. J. Porte, M. J.H. Slooff, H. van Goor, and A. van den Berg (2005)
Clin. Cancer Res. 11, 4067-4073
 |  Abstract »  |  Full Text »  |  PDF »

Protease-activated Receptor-1 Signaling by Activated Protein C in Cytokine-perturbed Endothelial Cells Is Distinct from Thrombin Signaling.

M. Riewald and W. Ruf (2005)
J. Biol. Chem. 280, 19808-19814
 |  Abstract »  |  Full Text »  |  PDF »

The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer.

M. J. Goodheart, J. M. Ritchie, S. L. Rose, J. P. Fruehauf, B. R. De Young, and R. E. Buller (2005)
Clin. Cancer Res. 11, 3733-3742
 |  Abstract »  |  Full Text »  |  PDF »

COX-2: A Molecular Target for Colorectal Cancer Prevention.

J. R. Brown and R. N. DuBois (2005)
J. Clin. Oncol. 23, 2840-2855
 |  Abstract »  |  Full Text »  |  PDF »

Hypoxia-inducible Factor-1{alpha} is Associated with Risk of Aggressive Behavior and Tumor Angiogenesis in Gastrointestinal Stromal Tumor.

W.-T. Chen, C.-J. Huang, M.-T. Wu, S.-F. Yang, Y.-C. Su, and C.-Y. Chai (2005)
Jpn. J. Clin. Oncol. 35, 207-213
 |  Abstract »  |  Full Text »  |  PDF »

Activin A Suppresses Neuroblastoma Xenograft Tumor Growth via Antimitotic and Antiangiogenic Mechanisms.

E. Panopoulou, C. Murphy, H. Rasmussen, E. Bagli, E. K. Rofstad, and T. Fotsis (2005)
Cancer Res. 65, 1877-1886
 |  Abstract »  |  Full Text »  |  PDF »

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

K. Podar and K. C. Anderson (2005)
Blood 105, 1383-1395
 |  Abstract »  |  Full Text »  |  PDF »

Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies.

H.-P. Gerber and N. Ferrara (2005)
Cancer Res. 65, 671-680
 |  Abstract »  |  Full Text »  |  PDF »

Is Oncogene Addiction Angiogenesis-dependent?.

J. FOLKMAN and S. RYEOM (2005)
Cold Spring Harb Symp Quant Biol 70, 389-397
 |  Abstract »  |  PDF »

Novel Antiangiogenic Therapies for Renal Cell Cancer.

M. S. Gordon (2004)
Clin. Cancer Res. 10, 6377S-6381S
 |  Abstract »  |  Full Text »  |  PDF »

CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer.

W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler (2004)
J. Clin. Pathol. 57, 965-969
 |  Abstract »  |  Full Text »  |  PDF »

p73{alpha} is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes.

A Oniscu, N Sphyris, R G Morris, S Bader, and D J Harrison (2004)
J. Clin. Pathol. 57, 492-498
 |  Abstract »  |  Full Text »  |  PDF »

Thromboxane A2 Receptor Agonists Antagonize the Proangiogenic Effects of Fibroblast Growth Factor-2: Role of Receptor Internalization, Thrombospondin-1, and {alpha}v{beta}3.

A. W. Ashton, Y. Cheng, A. Helisch, and J. A. Ware (2004)
Circ. Res. 94, 735-742
 |  Abstract »  |  Full Text »  |  PDF »

HIFs and tumors--causes and consequences.

G. Hopfl, O. Ogunshola, and M. Gassmann (2004)
Am J Physiol Regulatory Integrative Comp Physiol 286, R608-R623
 |  Abstract »  |  Full Text »  |  PDF »

Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase Substrate 1 Regulates the Migration of Langerhans Cells from the Epidermis to Draining Lymph Nodes.

A. Fukunaga, H. Nagai, T. Noguchi, H. Okazawa, T. Matozaki, X. Yu, C. F. Lagenaur, N. Honma, M. Ichihashi, M. Kasuga, et al. (2004)
J. Immunol. 172, 4091-4099
 |  Abstract »  |  Full Text »  |  PDF »

{alpha}4{beta}1 Integrin Mediates Selective Endothelial Cell Responses to Thrombospondins 1 and 2 In Vitro and Modulates Angiogenesis In Vivo.

M. J. Calzada, L. Zhou, J. M. Sipes, J. Zhang, H. C. Krutzsch, M. L. Iruela-Arispe, D. S. Annis, D. F. Mosher, and D. D. Roberts (2004)
Circ. Res. 94, 462-470
 |  Abstract »  |  Full Text »  |  PDF »

Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression.

Y. Hamano, H. Sugimoto, M. A. Soubasakos, M. Kieran, B. R. Olsen, J. Lawler, A. Sudhakar, and R. Kalluri (2004)
Cancer Res. 64, 1570-1574
 |  Abstract »  |  Full Text »  |  PDF »

Thombospondin-1 Disrupts Estrogen-Induced Endothelial Cell Proliferation and Migration and Its Expression Is Suppressed by Estradiol.

K. Sengupta, S. Banerjee, N. K. Saxena, and S. K. Banerjee (2004)
Mol. Cancer Res. 2, 150-158
 |  Abstract »  |  Full Text »  |  PDF »

CD47 Mediates Killing of Breast Tumor Cells via Gi-Dependent Inhibition of Protein Kinase A.

P. P. Manna and W. A. Frazier (2004)
Cancer Res. 64, 1026-1036
 |  Abstract »  |  Full Text »  |  PDF »

Microenvironmental and cellular consequences of altered blood flow in tumours.

N Raghunand, R A Gatenby, and R J Gillies (2003)
Br. J. Radiol. 76, S11-S22
 |  Abstract »  |  Full Text »  |  PDF »

Angiosuppressive and Angiostimulatory Effects Exerted by Synthetic Partial Sequences of Endostatin.

L. Morbidelli, S. Donnini, F. Chillemi, A. Giachetti, and M. Ziche (2003)
Clin. Cancer Res. 9, 5358-5369
 |  Abstract »  |  Full Text »  |  PDF »

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Y.-W. Zhang, Y. Su, O. V. Volpert, and G. F. V. Woude (2003)
PNAS 100, 12718-12723
 |  Abstract »  |  Full Text »  |  PDF »

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.

G. Bocci, G. Francia, S. Man, J. Lawler, and R. S. Kerbel (2003)
PNAS 100, 12917-12922
 |  Abstract »  |  Full Text »  |  PDF »

Angiogenesis in Endocrine Tumors.

H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass (2003)
Endocr. Rev. 24, 600-632
 |  Abstract »  |  Full Text »  |  PDF »

Methylation-associated Silencing of the Thrombospondin-1 Gene in Human Neuroblastoma.

Q.-W. Yang, S. Liu, Y. Tian, H. R. Salwen, A. Chlenski, J. Weinstein, and S. L. Cohn (2003)
Cancer Res. 63, 6299-6310
 |  Abstract »  |  Full Text »  |  PDF »

Angiogenesis: Basic Mechanisms and Clinical Applications.

V. Chhokar and A. L. Tucker (2003)
Seminars in Cardiothoracic and Vascular Anesthesia 7, 253-280
 |  Abstract »  |  PDF »

Down-Regulation of Nitric Oxide Synthase-2 and Cyclooxygenase-2 Pathways by p53 in Squamous Cell Carcinoma.

O. Gallo, N. Schiavone, L. Papucci, I. Sardi, L. Magnelli, A. Franchi, E. Masini, and S. Capaccioli (2003)
Am. J. Pathol. 163, 723-732
 |  Abstract »  |  Full Text »  |  PDF »

PTEN and Phosphatidylinositol 3'-Kinase Inhibitors Up-Regulate p53 and Block Tumor-induced Angiogenesis: Evidence for an Effect on the Tumor and Endothelial Compartment.

J. D. Su, L. D. Mayo, D. B. Donner, and D. L. Durden (2003)
Cancer Res. 63, 3585-3592
 |  Abstract »  |  Full Text »  |  PDF »

Enhanced Tumor Suppression by a p14ARF/p53 Bicistronic Adenovirus through Increased p53 Protein Translation and Stability.

Y. Huang, T. Tyler, N. Saadatmandi, C. Lee, P. Borgstrom, and R. A. Gjerset (2003)
Cancer Res. 63, 3646-3653
 |  Abstract »  |  Full Text »  |  PDF »

p73 Overexpression and Angiogenesis in Human Colorectal Carcinoma.

M. Guan, H.-X. Peng, B. Yu, and Y. Lu (2003)
Jpn. J. Clin. Oncol. 33, 215-220
 |  Abstract »  |  Full Text »  |  PDF »

PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli.

T. Abe, K. Terada, H. Wakimoto, R. Inoue, E. Tyminski, R. Bookstein, J. P. Basilion, and E. A. Chiocca (2003)
Cancer Res. 63, 2300-2305
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Colon Tumor Progression and Angiogenesis by the Ink4a/Arf Locus.

S. L. Gibson, C. Y. Dai, H.-W. Lee, R. A. DePinho, M. S. Gee, W. M. F. Lee, E. E. Furth, C. Brensinger, and G. H. Enders (2003)
Cancer Res. 63, 742-746
 |  Abstract »  |  Full Text »  |  PDF »

Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APCMin/+ mouse model.

L. S. Gutierrez, M. Suckow, J. Lawler, V. A. Ploplis, and F. J. Castellino (2003)
Carcinogenesis 24, 199-207
 |  Abstract »  |  Full Text »  |  PDF »

SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis.

A. Chlenski, S. Liu, S. E. Crawford, O. V. Volpert, G. H. DeVries, A. Evangelista, Q. Yang, H. R. Salwen, R. Farrer, J. Bray, et al. (2002)
Cancer Res. 62, 7357-7363
 |  Abstract »  |  Full Text »  |  PDF »

Angiogenesis in epithelian ovarian cancer.

E S Bamberger and C W Perrett (2002)
Mol. Pathol. 55, 348-359
 |  Abstract »  |  Full Text »  |  PDF »

The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin.

J.-C. Zhang, F. Donate, X. Qi, N. P. Ziats, J. C. Juarez, A. P. Mazar, Y.-P. Pang, and K. R. McCrae (2002)
PNAS 99, 12224-12229
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Prostate Tumor Angiogenesis by the Tumor Suppressor CEACAM1.

O. Volpert, W. Luo, T.-J. Liu, V. T. Estrera, C. Logothetis, and S.-H. Lin (2002)
J. Biol. Chem. 277, 35696-35702
 |  Abstract »  |  Full Text »  |  PDF »

Single nucleotide polymorphism seeking long term association with complex disease.

B. W. Kirk, M. Feinsod, R. Favis, R. M. Kliman, and F. Barany (2002)
Nucleic Acids Res. 30, 3295-3311
 |  Abstract »  |  Full Text »  |  PDF »

Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

A Rice and C M Quinn (2002)
J. Clin. Pathol. 55, 569-574
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of Angiogenesis in Diabetic Retinopathy: Possible Balance Between Vascular Endothelial Growth Factor and Endostatin.

H. Noma, H. Funatsu, H. Yamashita, S. Kitano, H. K. Mishima, and S. Hori (2002)
Arch Ophthalmol 120, 1075-1080
 |  Abstract »  |  Full Text »  |  PDF »

The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development.

R. N. McKeller, J. L. Fowler, J. J. Cunningham, N. Warner, R. J. Smeyne, F. Zindy, and S. X. Skapek (2002)
PNAS 99, 3848-3853
 |  Abstract »  |  Full Text »  |  PDF »

Clinical Link Between p53and Angiogenesis in Lung Cancer.

S. J. Freemantle and E. Dmitrovsky (2002)
J. Clin. Oncol. 20, 883-884
 |  Full Text »  |  PDF »

Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer.

A. Yuan, C.-J. Yu, K.-T. Luh, S.-H. Kuo, Y.-C. Lee, and P.-C. Yang (2002)
J. Clin. Oncol. 20, 900-910
 |  Abstract »  |  Full Text »  |  PDF »

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.

Y.-T. Tai, K. Podar, D. Gupta, B. Lin, G. Young, M. Akiyama, and K. C. Anderson (2002)
Blood 99, 1419-1427
 |  Abstract »  |  Full Text »  |  PDF »

Overexpression of Thrombospondin-1 Reduces Growth and Vascular Index but not Perfusion in Glioblastoma.

M. Kragh, B. Quistorff, M. Tenan, E. G. Van Meir, and E. G. Kristjansen (2002)
Cancer Res. 62, 1191-1195
 |  Abstract »  |  Full Text »  |  PDF »

Discovery of Type IV Collagen Non-collagenous Domains as Novel Integrin Ligands and Endogenous Inhibitors of Angiogenesis.

R. KALLURI (2002)
Cold Spring Harb Symp Quant Biol 67, 255-266
 |  Abstract »  |  PDF »

Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis.

E. Fosslien (2001)
Ann. Clin. Lab. Sci. 31, 325-348
 |  Abstract »  |  Full Text »  |  PDF »

Selective Inactivation of p53 Facilitates Mouse Epithelial Tumor Progression without Chromosomal Instability.

X. Lu, G. Magrane, C. Yin, D. N. Louis, J. Gray, and T. Van Dyke (2001)
Mol. Cell. Biol. 21, 6017-6030
 |  Abstract »  |  Full Text »  |  PDF »

Central Role of p53 on Regulation of Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Expression in Mammary Carcinoma.

S. Pal, K. Datta, and D. Mukhopadhyay (2001)
Cancer Res. 61, 6952-6957
 |  Abstract »  |  Full Text »  |  PDF »

Thrombospondin-1 and -2 Messenger RNA Expression in Invasive Cervical Cancer: Correlation with Angiogenesis and Prognosis.

J. Kodama, I. Hashimoto, N. Seki, A. Hongo, M. Yoshinouchi, H. Okuda, and T. Kudo (2001)
Clin. Cancer Res. 7, 2826-2831
 |  Abstract »  |  Full Text »  |  PDF »

Adenoviral Vector Expressing Murine Angiostatin Inhibits a Model of Breast Cancer Metastatic Growth in the Lungs of Mice.

S. Gyorffy, K. Palmer, and J. Gauldie (2001)
Am. J. Pathol. 159, 1137-1147
 |  Abstract »  |  Full Text »  |  PDF »

High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer.

J. A. Foekens, H. A. Peters, N. Grebenchtchikov, M. P. Look, M. E. Meijer-van Gelder, A. Geurts-Moespot, T. H. van der Kwast, C. G. J. Sweep, and J. G. M. Klijn (2001)
Cancer Res. 61, 5407-5414
 |  Abstract »  |  Full Text »  |  PDF »

Expresson of Vascular Endothelial Growth Factor, Its Receptors (FLT-1, KDR) and TSP-1 Related to Microvessel Density and Patient Outcome in Vertical Growth Phase Melanomas.

O. Straume and L. A. Akslen (2001)
Am. J. Pathol. 159, 223-235
 |  Abstract »  |  Full Text »  |  PDF »

A New Link in Ovarian Cancer Angiogenesis: Lysophosphatidic Acid and Vascular Endothelial Growth Factor Expression.

J. Folkman (2001)
J Natl Cancer Inst 93, 734-735
 |  Full Text »  |  PDF »

Pterygia Pathogenesis: Corneal Invasion by Matrix Metalloproteinase Expressing Altered Limbal Epithelial Basal Cells.

N. Dushku, M. K. John, G. S. Schultz, and T. W. Reid (2001)
Arch Ophthalmol 119, 695-706
 |  Abstract »  |  Full Text »  |  PDF »

Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis.

J. A. Cerrato, W.K. A. Yung, and T.-J. Liu (2001)
Neuro-oncol 3, 113-122
 |  Abstract »  |  PDF »

The Expression of Vascular Endothelial Growth Factor Correlates with Mutant p53 and Poor Prognosis in Human Breast Cancer.

B. K. Linderholm, T. Lindahl, L. Holmberg, S. Klaar, J. Lennerstrand, R. Henriksson, and J. Bergh (2001)
Cancer Res. 61, 2256-2260
 |  Abstract »  |  Full Text »

RB2/p130 Gene-enhanced Expression Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Vivo.

P. P. Claudio, P. Stiegler, C. M. Howard, C. Bellan, C. Minimo, G. M. Tosi, J. Rak, A. Kovatich, Paola De Fazio, P. Micheli, et al. (2001)
Cancer Res. 61, 462-468
 |  Abstract »  |  Full Text »

Expression of the Angiogenesis Markers Vascular Endothelial Growth Factor-A, Thrombospondin-1, and Platelet-Derived Endothelial Cell Growth Factor in Human Sporadic Adrenocortical Tumors: Correlation with Genotypic Alterations.

F. de Fraipont, M. El Atifi, C. Gicquel, X. Bertagna, E. M. Chambaz, and J. J. Feige (2000)
J. Clin. Endocrinol. Metab. 85, 4734-4741
 |  Abstract »  |  Full Text »

Nitric Oxide Synthase, Cyclooxygenase 2, and Vascular Endothelial Growth Factor in the Angiogenesis of Non-Small Cell Lung Carcinoma.

A. J. Marrogi, W. D. Travis, J. A. Welsh, M. A. Khan, H. Rahim, H. Tazelaar, P. Pairolero, V. Trastek, J. Jett, N. E. Caporaso, et al. (2000)
Clin. Cancer Res. 6, 4739-4744
 |  Abstract »  |  Full Text »

To Advertise   |   Find Products